Inventiva (IVA) Competitors $3.35 -0.03 (-0.89%) Closing price 07/11/2025 03:55 PM EasternExtended Trading$3.36 +0.01 (+0.27%) As of 07/11/2025 04:01 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsFDA EventsHeadlinesOwnershipSEC FilingsShort InterestTrendsBuy This Stock IVA vs. BGM, NAGE, AMPH, DYN, ABCL, PAHC, WVE, ELVN, VERV, and NTLAShould you be buying Inventiva stock or one of its competitors? The main competitors of Inventiva include BGM Group (BGM), Niagen Bioscience (NAGE), Amphastar Pharmaceuticals (AMPH), Dyne Therapeutics (DYN), AbCellera Biologics (ABCL), Phibro Animal Health (PAHC), WAVE Life Sciences (WVE), Enliven Therapeutics (ELVN), Verve Therapeutics (VERV), and Intellia Therapeutics (NTLA). These companies are all part of the "pharmaceutical products" industry. Inventiva vs. Its Competitors BGM Group Niagen Bioscience Amphastar Pharmaceuticals Dyne Therapeutics AbCellera Biologics Phibro Animal Health WAVE Life Sciences Enliven Therapeutics Verve Therapeutics Intellia Therapeutics BGM Group (NASDAQ:BGM) and Inventiva (NASDAQ:IVA) are both small-cap medical companies, but which is the better business? We will compare the two businesses based on the strength of their media sentiment, earnings, dividends, valuation, institutional ownership, profitability, risk and analyst recommendations. Do analysts recommend BGM or IVA? Inventiva has a consensus target price of $10.40, suggesting a potential upside of 210.45%. Given Inventiva's stronger consensus rating and higher probable upside, analysts clearly believe Inventiva is more favorable than BGM Group.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score BGM Group 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00Inventiva 0 Sell rating(s) 1 Hold rating(s) 4 Buy rating(s) 0 Strong Buy rating(s) 2.80 Is BGM or IVA more profitable? Company Net Margins Return on Equity Return on Assets BGM GroupN/A N/A N/A Inventiva N/A N/A N/A Does the media favor BGM or IVA? In the previous week, Inventiva had 4 more articles in the media than BGM Group. MarketBeat recorded 7 mentions for Inventiva and 3 mentions for BGM Group. BGM Group's average media sentiment score of 0.44 beat Inventiva's score of 0.28 indicating that BGM Group is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment BGM Group 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral Inventiva 0 Very Positive mention(s) 1 Positive mention(s) 5 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Which has preferable earnings and valuation, BGM or IVA? BGM Group has higher revenue and earnings than Inventiva. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioBGM Group$25.10M36.06-$1.44MN/AN/AInventiva$9.95M32.21-$199.34MN/AN/A Which has more volatility & risk, BGM or IVA? BGM Group has a beta of 1.29, suggesting that its share price is 29% more volatile than the S&P 500. Comparatively, Inventiva has a beta of 0.73, suggesting that its share price is 27% less volatile than the S&P 500. Do institutionals & insiders hold more shares of BGM or IVA? 19.1% of Inventiva shares are owned by institutional investors. 58.7% of BGM Group shares are owned by insiders. Comparatively, 32.0% of Inventiva shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term. SummaryBGM Group beats Inventiva on 6 of the 11 factors compared between the two stocks. Get Inventiva News Delivered to You Automatically Sign up to receive the latest news and ratings for IVA and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding IVA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart IVA vs. The Competition Export to ExcelMetricInventivaMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$323.34M$2.99B$5.61B$9.11BDividend YieldN/A2.39%5.24%4.02%P/E RatioN/A20.5827.9620.25Price / Sales32.21292.00430.8999.65Price / CashN/A42.8637.4658.16Price / Book-2.777.638.045.49Net Income-$199.34M-$55.05M$3.18B$250.27M7 Day Performance9.48%8.54%3.67%4.80%1 Month Performance-1.18%5.51%4.09%7.68%1 Year Performance25.00%2.03%29.58%16.36% Inventiva Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)IVAInventiva3.1893 of 5 stars$3.35-0.9%$10.40+210.4%+22.9%$323.34M$9.95M0.00100News CoverageBGMBGM GroupN/A$10.59-11.5%N/AN/A$1.16B$25.10M0.00298NAGENiagen Bioscience1.3362 of 5 stars$14.41+1.3%$19.50+35.3%N/A$1.12B$99.60M84.76120AMPHAmphastar Pharmaceuticals4.3237 of 5 stars$22.96-0.5%$32.33+40.8%-44.7%$1.09B$731.97M8.322,028DYNDyne Therapeutics3.4216 of 5 stars$9.52-0.5%$41.13+332.0%-79.4%$1.09BN/A-2.65100Analyst ForecastABCLAbCellera Biologics2.4382 of 5 stars$3.43-5.0%$8.33+143.0%+28.1%$1.08B$28.83M-6.12500Analyst RevisionHigh Trading VolumePAHCPhibro Animal Health4.0515 of 5 stars$25.54-0.5%$21.80-14.6%+76.0%$1.04B$1.02B32.741,940Gap UpWVEWAVE Life Sciences4.5421 of 5 stars$6.50-2.5%$20.50+215.4%+29.8%$1.04B$108.30M-7.74240ELVNEnliven Therapeutics2.8274 of 5 stars$20.06-3.0%$39.60+97.4%-6.7%$1.01BN/A-10.4550Insider TradeVERVVerve Therapeutics3.0512 of 5 stars$11.23-0.6%$14.57+29.8%+73.2%$1.01B$32.33M-5.32110NTLAIntellia Therapeutics4.3816 of 5 stars$9.38-1.9%$33.37+255.7%-53.2%$990.25M$57.88M-1.79600 Related Companies and Tools Related Companies BGM Competitors NAGE Competitors AMPH Competitors DYN Competitors ABCL Competitors PAHC Competitors WVE Competitors ELVN Competitors VERV Competitors NTLA Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:IVA) was last updated on 7/12/2025 by MarketBeat.com Staff From Our Partners3..2..1.. AI 2.0 ignition (don’t sleep on this)I just put together an urgent new presentation that you need to see right away. In short: I believe we are...Timothy Sykes | SponsoredMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredThis Signal Only Flashes Once Every 4 Years – And It Just TriggeredThis same signal has appeared twice before in the past 8 years — both times, it kicked off major moves in cryp...Crypto Swap Profits | SponsoredTrump’s treachery Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | SponsoredBuffett’s $325 Billion Cash Problem — Solved by Gold?A bombshell announcement is just weeks away — and it could send shockwaves through the gold market. Most inves...Golden Portfolio | SponsoredTrump’s New Order Could Boost Social Security Benefits by 400%If you collect—or plan to collect—Social Security, you need to see this. A new initiative tied to President...InvestorPlace | SponsoredThink you missed gold’s boom? Think againIf you've been watching gold's historic run and wondering if it's too late… I've got good news. Because the...Investors Alley | SponsoredElon’s NEXT Big IPO?Cancel your internet TODAY!? Take your latest internet bill and light it on fire… then count the seconds it...Banyan Hill Publishing | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Inventiva S.A. Sponsored ADR Please log in to your account or sign up in order to add this asset to your watchlist. Share Inventiva With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
